Ardelyx Announces Participation in Key Investor Conferences

Ardelyx's Commitment to Investor Engagement

WALTHAM, Mass. — Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company, is excited to announce its engagement in several impactful investor conferences. Founded to innovate and commercialize first-in-class medicines, Ardelyx is dedicated to addressing critical unmet medical needs. Through these events, the company aims to connect with investors and share its future developments.

Upcoming Conferences and Presentation Details

Ardelyx will participate in the following events, enabling stakeholders to gain insights into the company’s progress and future initiatives:

Leerink Partners 2025 Global Healthcare Conference

This prominent conference is set to take place in Miami, FL. Ardelyx is scheduled to present on Tuesday, March 11 at 8:00 a.m. ET, followed by one-on-one meetings that same day. Attendees can learn about the company's innovative approaches during this session.

Jefferies Biotech on the Beach Summit

Also in Miami, FL, Ardelyx will host one-on-one meetings on Wednesday, March 12. This summit represents another valuable opportunity for investors to engage with Ardelyx representatives and discuss the company’s innovative product pipeline.

Barclays Annual Global Healthcare Conference

Following the previous events, Ardelyx will take the stage at the Barclays 27th Annual Global Healthcare Conference in Miami, FL. The company’s fireside chat is scheduled for Thursday, March 13 at 10:00 a.m. ET, with additional one-on-one meetings available that day as well. The chat will delve into advancements in Ardelyx's strategies and recent successes.

Investors and interested parties can access the live webcasts of the presentations through the Events and Presentations section on the Ardelyx website. Replays will be available for 30 days following each event, ensuring those who may miss the live sessions can stay informed.

About Ardelyx, Inc.

Ardelyx has emerged as a leader in the biopharmaceutical space, delivering innovative solutions to address significant health challenges. The company boasts two approved commercial products in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor). Additionally, Ardelyx collaborates with Kyowa Kirin to commercialize PHOZEVEL (tenapanor) for managing hyperphosphatemia in Japan. Furthermore, the company has submitted a New Drug Application for tenapanor regarding hyperphosphatemia in China in collaboration with Fosun Pharma.

Ardelyx is also partnered with Knight Therapeutics to commercialize IBSRELA in Canada. This robust network of partnerships showcases Ardelyx's commitment to extending its innovative solutions globally.

Investor and Media Contacts

For more information, inquiries can be directed to Caitlin Lowie at Ardelyx. She can be reached via email for any additional questions concerning the company's presentation schedule or product information.

Frequently Asked Questions

What is Ardelyx's mission?

Ardelyx aims to discover and commercialize innovative first-in-class medicines to meet critical unmet medical needs.

Which conferences is Ardelyx participating in?

Ardelyx will participate in the Leerink Partners Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and Barclays Annual Global Healthcare Conference.

Where can I access Ardelyx's conference presentations?

The live webcasts of the presentations will be available on the Ardelyx website, with replays accessible for 30 days post-event.

What products has Ardelyx commercialized?

Ardelyx has commercialized IBSRELA and XPHOZAH in the U.S. and has various partnerships for its products in international markets.

Who can I contact for more information about Ardelyx?

For further inquiries, Caitlin Lowie at Ardelyx can be contacted for detailed information regarding presentations and products.

About The Author

Even at just 28 years old, Lucas Young has made a name for himself as a writer and financial expert. Lucas is a gifted communicator of difficult financial ideas and has written a number of well-received books and articles that appeal to both new and experienced investors. The financial world has come to rely on his perceptive analysis and useful counsel. Many people have been enabled to make wise investment decisions by Lucas's commitment to financial literacy and his ability to demystify the complexities of the market. Lucas is still dedicated to advising and teaching people on their financial journeys as he shares his knowledge.

Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.